SEATTLE, WA--(Marketwired - Sep 19, 2013) - Atossa Genetics, Inc. (
Chris Destro, Vice President, Sales and Marketing for Atossa, stated, "The Pri-Med East show is a strategic venue and opportunity as we continue to market the ForeCYTE Breast Health Test. We look forward to having representatives demonstrate our collection device and to expand on the clinical value of our test to the primary care providers attending the show."
The ForeCYTE Breast Health Test, developed and marketed by Atossa's subsidiary, The National Reference Laboratory for Breast Health, detects reversible precancerous conditions in the breast up to eight years before they become cancer. The test uses Atossa's hand-held, FDA Class II medical device that is quick, painless, and non-invasive and can be administered during an OB/GYN office visit. Unlike mammograms, which are commonly recommended for women starting at age 40 to 50, the ForeCYTE Breast Health Test is more age agnostic, uses no radiation and does not require invasive biopsy needles or surgical incisions. To view a video about the ForeCYTE Test, click here: https://vimeo.com/62365818.
About the Pri-Med 2013 Conference & Exhibition
The Pri-Med Conference & Exhibition offers low-cost continuing medical education in a flexible format. The CME conference schedule is designed to maximize participants' time out of the office, providing clinical updates on the disease states and patients treated daily.
Topics of interest for this conference include:
- Women's health
- Pediatric and adolescent medicine
- Cardiology for primary care clinicians
- And many more topics for CME or CE credit
About the ForeCYTE Breast Health Test
The ForeCYTE Breast Health Test, intended for the 110 million women in the U.S. ages 18 to 73, is a painless, quick and non-invasive procedure that can be done in a physician's office. The test specimens are then analyzed at Atossa's laboratory, The National Reference Laboratory for Breast Health, Inc. (NRLBH), which can provide vital early detection of cancer or pre-cancerous conditions that may progress to cancer over an approximately eight year period and before cancer can be detected by mammography or other means and without the risks of radiation, especially in women younger than age 50. No invasive biopsy needles or open surgical incisions are used in the Atossa test.
Just as the Pap smear has reduced cervical cancer rates by over 70 percent, becoming the most successful screening test in medicine, the goal of Atossa Genetics is to reduce the stubbornly high rate of breast cancer through the early detection of the precursor changes that can lead to breast cancer and the treatment of those early changes. For more information, please visit getforecyte.com.
Atossa's ForeCYTE Breast Health Test is available through physicians nationwide.
About Atossa Genetics, Inc.
Atossa Genetics, Inc. is focused on preventing breast cancer through the commercialization of patented, FDA-designated Class II diagnostic medical devices and, through its wholly-owned subsidiary, The NRLBH, patented, laboratory developed tests that can detect precursors to breast cancer up to eight years before mammography.
The NRLBH is a CLIA-certified high-complexity molecular diagnostic laboratory located in Seattle, Washington.
For additional information, on Atossa and the NRLBH, please visit www.atossagenetics.com and www.nrlbh.com. For further information on the ForeCYTE Breast Health Test, please visit www.getforecyte.com.
Forward-looking statements in this press release are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with actions by the FDA, regulatory clearances, responses to regulatory matters, Atossa's ability to continue to manufacture and sell its products, the efficacy of Atossa's products and services, the market demand for and acceptance of Atossa's products and services, performance of distributors and other risks detailed from time to time in Atossa's filings with the Securities and Exchange Commission, including without limitation its periodic reports on Form 10-K and 10-Q, each as amended and supplemented from time to time.
- Health Care Industry
- breast cancer
- Breast Health